These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 11899389)

  • 1. Treatment of metastatic bone disease in breast cancer: bisphosphonates.
    Diel IJ; Solomayer EF; Bastert G
    Clin Breast Cancer; 2000 Apr; 1(1):43-51. PubMed ID: 11899389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic value of aredia in treatment of breast carcinoma].
    Diel IJ
    Med Klin (Munich); 2000 Oct; 95 Suppl 2():9-18. PubMed ID: 11089382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer.
    Paterson AH; Kanis JA; Powles TJ; McCloskey E; Hanson J; Ashley S
    Can J Oncol; 1995 Dec; 5 Suppl 1():54-7. PubMed ID: 8853526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trials in metastatic breast cancer to bone: past--present--future.
    Body JJ
    Can J Oncol; 1995 Dec; 5 Suppl 1():16-27. PubMed ID: 8853520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 2: Clinical studies and economic analyses.
    Saba N; Khuri F
    Oncology; 2005; 68(1):18-22. PubMed ID: 15775689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo antiresorptive effects of bisphosphonates in metastatic bone disease.
    Kanakis I; Kousidou OCh; Karamanos NK
    In Vivo; 2005; 19(1):311-8. PubMed ID: 15796191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.
    Body JJ; Bartl R; Burckhardt P; Delmas PD; Diel IJ; Fleisch H; Kanis JA; Kyle RA; Mundy GR; Paterson AH; Rubens RD
    J Clin Oncol; 1998 Dec; 16(12):3890-9. PubMed ID: 9850035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.
    Hortobagyi GN; Theriault RL; Porter L; Blayney D; Lipton A; Sinoff C; Wheeler H; Simeone JF; Seaman J; Knight RD
    N Engl J Med; 1996 Dec; 335(24):1785-91. PubMed ID: 8965890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approaches to managing bone metastases from breast cancer: the role of bisphosphonates.
    Mystakidou K; Katsouda E; Stathopoulou E; Vlahos L
    Cancer Treat Rev; 2005 Jun; 31(4):303-11. PubMed ID: 16039956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints.
    Major PP; Cook R
    Am J Clin Oncol; 2002 Dec; 25(6 Suppl 1):S10-8. PubMed ID: 12562046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The role of adjuvant clodronate therapy for prevention of bone metastasis in breast cancer].
    Horváth Z
    Magy Onkol; 2002; 46(4):361-4. PubMed ID: 12563361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases].
    Tubiana-Hulin M; Beuzeboc P; Mauriac L; Barbet N; Frenay M; Monnier A; Pion JM; Switsers O; Misset JL; Assadourian S; Bessa E
    Bull Cancer; 2001 Jul; 88(7):701-7. PubMed ID: 11495824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
    Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
    J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonates: clinical experience.
    Coleman RE
    Oncologist; 2004; 9 Suppl 4():14-27. PubMed ID: 15459426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current use of bisphosphonates in clinical oncology].
    Vrbanec D; Plestina S; Belev B; Unusić J; Pavlinić-Diminić V
    Lijec Vjesn; 1999; 121(9-10):296-301. PubMed ID: 19658372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The effect of bisphosphonates on pain relief in patients with bone metastases: A status article based on the Cochrane analysis: "Bisphosphonates for the relief of pain secondary to bone metastasis"].
    Ejlertsen B; Kristensen B
    Ugeskr Laeger; 2003 May; 165(20):2089-91. PubMed ID: 12812098
    [No Abstract]   [Full Text] [Related]  

  • 18. Bone metastases, general and clinical issues.
    Greco C; Forte L; Erba P; Mariani G
    Q J Nucl Med Mol Imaging; 2011 Aug; 55(4):337-52. PubMed ID: 21738111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonates in the prevention and treatment of bone metastases.
    Ramaswamy B; Shapiro CL
    Oncology (Williston Park); 2003 Sep; 17(9):1261-70; discussion 1270-2, 1277-8, 1280. PubMed ID: 14569853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bone metastases].
    Jensen AB; Kamby C; Hansen B; Keller J
    Ugeskr Laeger; 2007 Oct; 169(44):3753-6. PubMed ID: 18028842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.